News & Insights
Check out the latest news from the Verge network.
2026 MedTech Innovator Asia Pacific Cohort Announced
MedTech Innovator, the world’s largest accelerator of medical technology companies, today announced that** 20 **high-potential medtech companies have been selected to participate in the **2026 Asia Pacific Accelerator Program**.
Smartphone App–Delivered Mindfulness-Based Intervention for Concussion in Adolescents (MBI-4-mTBI): Feasibility Randomized Controlled Trial
Mobio Interactive (platform: Dawn, formerly AmDTx), in partnership with the CHEO Research Institute (https://ca.linkedin.com/company/cheo-research), has published feasibility results for a digital therapeutic (DTx) targeting adolescents aged 12–18 with persisting symptoms after a concussion (PSAC). The Health Canada-regulated, blinded RCT results, published in JMIR Publications (https://rehab.jmir.org/2026/1/e84623), demonstrated the following: 90% retention for 4-week outcomes, 75% participant credibility rating, and 0 reported adverse events. Adherence was recorded at 60%, identifying a target area for UX refinement during weeks two and three post-injury. Classified as Software as a Medical Device (SaMD), the Dawn platform aims to provide scalable, low-burden adjunct care and triage patients to eliminate specialist waitlists. These feasibility benchmarks support the implementation of a subsequent full-scale efficacy RCT.
Advancing the Frontier of Computational Pathology: The Launch of Imagenomix
Imagenomix Corp, a spin-off from NYU Langone Health, has officially launched following the closing of its Seed funding round. The round was led by [Modi Ventures](https://www.linkedin.com/company/modi-venture-partners) and supported by [Verge HealthTech Fund](https://sg.linkedin.com/company/verge-healthtech-fund), [Metavallon VC](https://gr.linkedin.com/company/metavallon), [NYU Technology Opportunities & Ventures](https://www.linkedin.com/company/nyu-technology-opportunities-and-ventures), [NYU Langone Health](https://www.linkedin.com/company/nyulangonehealth), and various NYU venture funds. External reports from [GenomeWeb](https://www.genomeweb.com/cancer/cancer-diagnostics-startup-imagenomix-raises-32m-seed-funding) indicate the funding amount was US$3.2M. The startup's AI-driven diagnostic platform was developed in the labs of Dr. [Matija Snuderl](https://www.linkedin.com/in/matija-snuderl-181335296), Dr. [Aristotelis Tsirigos](https://www.linkedin.com/in/aristotelistsirigos), and Dr. [Daniel Orringer](https://www.linkedin.com/in/daniel-orringer-688a61132). The technology aims to bridge the "tissue failure" gap by decoding molecular genotypes directly from standard H&E slides, providing molecular-grade diagnostic insights to clinicians. Key operational momentum includes: - **Pharma Partnerships**: Launching a clinical trial in Breast Cancer via [PathPresenter](https://www.linkedin.com/company/pathpresenter) and supporting Alterome Therapeutics. - **Infrastructure**: A multi-year collaboration with [Proscia](https://www.linkedin.com/company/proscia) to release a Lung Classifier in 2026. - **Diagnostic Scope**: A roadmap focusing on Lung, Brain, and Breast cancer diagnostics. Further details are available via [Precision Medicine Online](https://www.precisionmedicineonline.com/precision-oncology/cancer-diagnostics-startup-imagenomix-raises-32m-seed-funding).
Benefit to society through research: Transforming psychosis care with digital innovation Careloop
The CareLoop project has received the award for "Outstanding benefit to society through research." The initiative aims to transform psychosis care by transitioning clinical support from reactive crisis response to a proactive, digital prevention model. Led by John Ainsworth, Sandra Bucci, and Shôn Lewis, the project is a collaborative effort involving The University of Manchester Faculty of Biology, Medicine and Health and the Manchester Institute of Innovation Research. The digital innovation focuses on improving patient outcomes through real-time monitoring and early intervention. Further details regarding the project's impact and methodology can be viewed here: https://www.youtube.com/watch?v=8GxKCiDWsD8
Expanding Access to NCD Care in India
reach52 has announced the launch of treatment initiatives for diabetes, hypertension, and chronic kidney disease across India, supported by core public health programs. The initiative addresses critical gaps in India’s healthcare system, where over 90 million people live with diabetes and hundreds of millions with hypertension. Statistics cited indicate that 43% of diabetics in India are undiagnosed, and only 12% of individuals with hypertension have their condition under control. To address these issues, reach52 is implementing community screening to close diagnosis gaps, patient education and adherence support, and Health Care Professional (HCP) training. The organization plans to scale access with further launches in the coming weeks. reach52 has previously documented insights from its rural community sites in Indonesia, South Africa, and Kenya (https://www.linkedin.com/pulse/november-newsletter-insights-from-our-trips-rural-community-sites-).
VitruvianMD publishes study on the validation of our AI-powered sperm selection tool
VitruvianMD has validated a breakthrough AI-powered tool capable of predicting sperm DNA fragmentation (SDF) without compromising cell viability—a significant leap over traditional, destructive testing methods like the TUNEL assay. By combining phase-contrast imaging with morphological analysis, the morphology-assisted ensemble model identifies sperm with intact DNA at **75% specificity**, allowing these high-quality cells to be used in real-time for IVF and ICSI procedures. This objective, quantitative approach addresses the high variability of manual assessment and the limitations of random selection, offering a more precise and non-invasive solution to improve outcomes in male fertility treatments.
Artificial Intelligence-Guided Personalized Gut Microbiome Modulation for Persistent Secondary Gastrointestinal Symptoms in Oncology Patients: Clinical Efficacy and Biological Correlates from a Prospective Validation Study
The study published in _Cancers_ provides a clinical validation of the AI-driven methodology central to **Nostra Biome**, demonstrating that personalized gut microbiome modulation can significantly alleviate persistent gastrointestinal distress and fatigue in oncology patients. By utilizing shotgun metagenomic sequencing and AI analysis to generate individualized dietary and supplement protocols, researchers observed a dramatic reduction in daily stool frequency and a near-doubling of patient energy levels, supported by the biological enrichment of anti-inflammatory bacteria like _Akkermansia_ and _Faecalibacterium prausnitzii_. For Nostra Biome, this research serves as a critical evidence base, transforming their "microbiome intelligence" platform from a wellness tool into a scientifically-backed clinical solution for precision supportive care in cancer survivorship.
Bnoon Fertility Announces First Baby Born in Saudi Arabia Using AI Technology in IVF
Bnoon Network of Fertility & Women’s Health Centers, a part of Global Fertility, has announced the first birth in Saudi Arabia resulting from the use of an AI-enabled sperm selection application during IVF treatment. This milestone aligns with the Kingdom's designation of 2026 as the 'Year of Artificial Intelligence.' The birth followed the implementation of the Vitruvian MD AI solution within Bnoon’s laboratories. The system utilizes algorithmic analysis to assess sperm motility, morphology, and DNA fragmentation to improve decision-making for embryologists. This technology is designed to increase precision in sperm selection, particularly for complex cases involving high DNA fragmentation or low sperm counts. Key highlights include: - **Clinical Success**: The system was tested over 12 months with more than 50 couples, showing improved fertilization rates in cases of poor sperm quality. - **Case Study**: The first child born via this system belonged to a couple where the father was diagnosed with high DNA fragmentation. - **Operational Efficiency**: Majd Abu Zant, CEO of Global Fertility, stated that AI reduces failed cycles, lowering the time and cost for patients. - **Strategic Alignment**: Group Medical Director Dr. Abdulaziz Alshahrani noted that the adoption of AI is part of a broader strategy to support [Vision 2030’s](https://hospitalsmagazine.com/bnoon-fertility-announces-first-baby-born-in-saudi-arabia-using-ai-technology-in-ivf/) medical innovation objectives. Bnoon performs over 5,000 IVF cycles annually and is currently expanding its network to include centers in Riyadh, Jeddah, Al Ahsa, Abha, and Madinah. A new flagship facility in Riyadh is expected to open in the first half of 2026, offering services supported by AI, robotics, and genetic testing.
Hello Inside pushes metabolic health into mainstream care with BARMER deal
Hello Inside is bringing metabolic health into mainstream clinical care through a partnership with BARMER, one of Germany’s largest statutory health insurers. Hello Inside is now available free of charge to millions of BARMER members, including a ZPP-certified program and their signature 21-day blood sugar challenge.
DocMorris enhances its leading AI-powered health platform by partnering with Hello Inside to address metabolic healthcare
[DocMorris](https://ch.linkedin.com/company/docmorris), Germany's largest digital pharmacy, has launched a new "Care" section in partnership with [Hello Inside](https://at.linkedin.com/company/helloinside). This integration provides 11 million active customers with tools for early metabolic health intervention and prevention. The new features inside the DocMorris app include a 5-minute metabolic check covering nutrition, movement, sleep, mindfulness, and body vitals, which generates a personalised health profile. Additionally, the app now features a library of science-based programmes focused on glucose, hormones, sugar metabolism, and menopause support. The objective is to move from symptom management to prevention at scale for conditions like Type 2 diabetes, cardiovascular disease, and obesity by connecting assessments directly to actions such as video consultations with doctors, pharmacist advice, or specific health products.
The startups turning Southeast Asia’s AI hype into working agents
BotMD got featured by Tech in Asia as part of the list of Southeast Asian startups building AI applications.
Cycle Syncing® Method is Clinically Shown to Reduce PMS Symptoms for 92% of participants in 60 days
FLO Living, in collaboration with femtech leaders Mira, Hello Inside, and Citruslabs, today announced results from the first-ever clinical study evaluating the Cycle Syncing® Method, demonstrating significant reductions in premenstrual syndrome (PMS) symptom burden and severity among the majority of participants within just two months.
Advertising Watchdogs Find Dorel’s AI-Related Claims Supported; Recommends Improvements to COPPA Notice and Consent Practices
On March 3, 2026, BBB National Programs’ National Advertising Division (NAD) and Children’s Advertising Review Unit (CARU) released findings from a joint inquiry into Dorel Juvenile Group, Inc. regarding its Maxi-Cosi branded Sibia and Starling Smart Bassinets. The inquiry reviewed AI-related advertising claims and data privacy practices for the [CryAssist™ technology](https://www.maxicosi.com) developed by Swiss-based Zoundream AG. NAD concluded that Dorel successfully supported its claims that the AI translates infant cries into specific categories (sleepy, fussy, gassy, agitated, or hungry) and that the data is handled securely through encryption and anonymization. However, CARU found that Dorel's practices were deficient under the Children’s Online Privacy Protection Act (COPPA). While security measures were deemed reasonable, Dorel lacked a compliant online privacy policy, direct notice to parents, and a verifiable parental consent mechanism. CARU recommended that Dorel implement these required procedures, and the company has stated it will comply with the decision. Full case details can be found at the [BBB National Programs case decision library](https://bbbprograms.org).
Digital care built to prevent mental health crisis and relapse
CareLoop Health was featured in the University of Manchester’s Research impact, shaped together series, which highlights collaborations where research, trust, and long-term partnerships create real-world impact. CareLoop Health is a smartphone-based real-time monitoring and relapse prevention platform designed to support people living with severe mental illness. Their AI-powered solution helps clinicians detect early warning signs and provide patients with timely interventions to avoid relapses. In this video, co-founder Sandra Bucci shares how CareLoop was built through close collaboration between patients, clinicians, statisticians, and engineers, all working toward a shared goal of improving mental healthcare.
The App That Knows You're Stressed Before You Do
Dr. Bechara Saab, CEO of [Mobio Interactive](https://sg.linkedin.com/company/mobio-interactive), details the company's focus on clinical efficacy over engagement metrics for mental health applications. Mobio began conducting placebo-controlled randomized controlled trials (RCTs) in 2016, with results published in [JMIR Mental Health](https://mental.jmir.org/) in 2019. The company has since completed nearly two dozen clinical trials, most of which are RCTs. Since 2021, Mobio has integrated fMRI imaging to investigate the biological mechanism of action of its asynchronous psychotherapy platform. Preliminary data shows functional changes in the prefrontal cortex and default mode network, specifically in pediatric patients following concussions. This approach aims to provide pharmaceutical-grade biological evidence for digital interventions. Mobio’s technology includes a facial biomarker-based AI for stress measurement, which has been validated for accuracy across diverse ages, genders, and skin tones. Dr. Saab emphasizes scientific transparency, noting that two failed RCTs provided critical data on the optimal timing of digital prescriptions and the necessity of adjunct support. A full discussion is available via [YouTube](https://www.youtube.com/watch?v=4V5rx7wexSk).
Hello Inside integrates Garmin data to map female metabolic health
Hello Inside, an AI-driven metabolic health platform for women, has integrated Garmin wearable data to provide deeper insights into glucose stability and hormonal health. The [integration](https://www.garmin.com/en-US/blog/health/garmin-smartwatch-data-enhances-user-insights-for-womens-metabolic-health-platform-hello-inside/) pulls biometric data from devices such as the [Venu 4](https://www.wareable.com/garmin/garmin-venu-4-review), [Forerunner 570](https://www.wareable.com/garmin/garmin-forerunner-570-review), and [Fenix 8](https://www.wareable.com/garmin/garmin-fenix-8-review) to combine with continuous glucose monitoring (CGM) and lifestyle data. The platform specifically targets metabolic shifts often overlooked in general health apps, such as those occurring during menstrual cycles, pregnancy, and perimenopause. Key features include a 'sleep-glucose' feedback loop to monitor how sleep disruptions affect insulin resistance, and the use of Garmin’s Women’s Health API to align metabolic insights with menstrual phases for real-time adjustments to nutrition and training.
Reflections from WEF Davos: Collaboration in the Brain House and the Future of Brain Economies
Mobio Interactive's CEO & Chief Scientist, Dr Bechara Saab, was invited by Davos Alzheimer's Collaborative to speak at the Brain House Davos 2026 during the World Economic Forum's Annual Meeting at Davos-Klosters, Switzerland. Bechara joined global leaders to discuss the Brain Economy, where cognitive health and resilience are foundational infrastructure critical to long-term prosperity in an increasingly AI-shaped world. This idea is central to the work at Mobio Interactive, where their AI-native platform uses real-time objective measures to provide scalable, personalized psychotherapy and remote monitoring.
Top MedTech Startups in the UK
The United Kingdom has established itself as a leading European hub for medical technology innovation (MedTech), featuring a thriving ecosystem that is revolutionising healthcare delivery and diagnostics. MedTech demand is high, driven by the NHS's quest for innovation, an aging population, and the incorporation of digital technologies like AI and robotics. This sector is vital to the UK economy, supporting jobs, exports, and the long-term viability of the NHS. The industry faces a severe skills shortage, requiring new certifications to train tens of thousands of needed regulatory specialists, data scientists, and AI experts by 2035. MedTech is important to enhancing national health outcomes and reducing health disparities. Top MedTech startups operating in the UK include: 1. **CHARM Therapeutics**: Develops small-molecule drugs against challenging therapeutic targets using DragonFold, a unique 3D deep learning technology. 2. **Anima Health**: A Care Enablement Platform offering tools (including batch SMS, video, and online consultation) to securely and swiftly manage caseloads and expedite clinical workflows. 3. **Medwise AI Ltd**: Provides immediate, evidence-based solutions to doctors at the point of treatment. It uses an agentic, non-generating application of large language models based strictly on verifiable, high-quality sources, eliminating the risk of hallucinations. 4. **XARlabs**: Transforms surgical procedures and training using a platform that integrates AI, XR (Extended Reality), and seamless medical device integration. 5. **Pheon Theraputics**: An antibody-drug conjugate (ADC) expert creating next-generation ADCs for various difficult-to-treat solid tumours. 6. **Care Hires**: Offers a location-based app and cloud software enabling health and social care providers to recruit on-demand care workers more cost-effectively than existing solutions, addressing major operational expenses. 7. **Ochre Bio**: A biotechnology firm focused on developing RNA treatments for long-term liver conditions, aiming to boost donor liver availability and reduce cirrhosis consequences through genetic deep phenotyping. 8. **CareLoop Health**: Provides real-time monitoring and relapse prevention technology for individuals with severe mental illness, designed to enhance care routes.
AI-Guided Multi-Omic Microbiome Modulation Improves Clinical and Inflammatory Outcomes in Refractory IBD: A Real-World Study
Nostra:Biome announced the publication of results from their interventional study focused on Inflammatory Bowel Disease (IBD). The study included 358 IBD patients, many of whom were refractory to multiple prior therapies. Participants showed major improvements in just three months. Nostra:Biome attributes these outcomes to their multi-omics platform, asserting it identified the previously unknown cause of the condition, positioning the findings as a new chapter in precision healthcare.
Migrevention at EHC2025: Advancing Headache Care through Digital Pathways
Migrevention shared exciting results at the 19th European Headache Congress in Lisbon, presenting a study titled 'Improving Headache Self-Management through a Digital Pathway: Post-Market Survey Results from an Estonian Primary Care Centre.' The research highlighted strong acceptance and significant benefits in self-management and workflow for clinicians using the Migrevention™ Digital Headache Clinic. This supports the growing role of digital pathways in modern headache care. Key collaborators included Ülemiste City, University of Tartu, and TalTech Digital Health MSc programme. The team, led by Prof. Mark Braschinsky, showcased how digital health is becoming a pivotal element in future headache management strategies.
Zoundream: The AI that deciphers a baby's cry
Zoundream is a Spanish startup that has developed technology to interpret the most likely causes of a baby's cry, aiming to transform these sounds into clinical indicators accessible from any home. Founded by Ana Laguna, a data scientist, the company emerged from her personal challenge as a new mother trying to understand her baby's cries. The technology analyzes the cry and quickly identifies potential reasons such as hunger, sleepiness, or discomfort, among others. It is now integrated into products from major brands like Philips and Motorola and is used in over 40 countries. Zoundream's technology not only aids parents but also has potential applications in medical diagnostics, such as detecting early signs of digestive issues or neurodevelopmental disorders.
H2 INC listed on the Emerging Stock Market, focusing on AI-powered chronic disease management platforms
慧康生活科技（H2 INC.）, a digital health management startup focusing on diabetes and chronic disease, announced its official OTC listing in Taiwan. Founded in 2013, the company has pioneered integrating AI with chronic disease management through apps and cloud platforms. H2 INC. has successfully accumulated over 1.6 million real-world blood glucose data entries, which support health policy implementation and monitoring in Taiwan. The company has expanded its services to corporate and insurance sectors, partnering with major companies like HITACHI and MITSUBISHI, and is collaborating with pharmaceutical giants like Sanofi and Novo Nordisk. With its flagship products, including a smart diabetes app and a portable injection device, H2 INC. is looking to further its reach in the Asia-Pacific market and is preparing for potential inclusion in Taiwan's National Health Insurance due to its significant clinical management contributions.
Can an AI-Powered Eye Exam Spot Alzheimer’s Decades Early?
The article discusses the potential of AI-powered retinal imaging, developed by RetiSpec, to detect Alzheimer's disease decades before symptoms appear. RetiSpec's technology utilizes standard cameras in optometrists' offices to analyze eye images for Alzheimer's-related biomarkers, such as amyloid, providing a non-invasive, accessible, and real-time diagnostic tool. This method could revolutionize early detection and treatment of Alzheimer's, offering a significant advantage over current invasive and expensive methods like PET scans and spinal taps. The technology is nearing regulatory approval and could soon be available in clinical settings, making early intervention possible.
New Leadership and Strategic Focus at BrainCapture
BrainCapture, a company specializing in EEG technology, announces a strategic shift towards AI integration in their products. Founder Tue Lehn-Schiøler transitions from CEO to Chief AI Officer to focus on AI development, while Paul Loomis, previously Chief Commercial Officer, steps up as the new CEO. This change aims to enhance the commercialization and scalability of their innovative EEG devices, promising to improve and save lives through advanced technology.
Health2Sync has created the "Smart Anti-Diabetes" App, penetrating the chronic disease platform market!
Health2Sync was featured on Business Today Taiwan for its work transforming how chronic diseases like diabetes are managed. Founded and led by Ed Deng, co-founder & CEO of Health2Sync and General Partner at Verge HealthTech Fund, the company began with Ed's personal mission to help families better manage diabetes. Today, it has grown into Asia’s leading comprehensive chronic disease management care platform, empowering more than 1.7 million users across Taiwan, Japan, Singapore, and Australia. Through its app, Health2Sync connects patients, healthcare providers, and insurers to deliver more continuous and data-driven care. 🏥
Understanding Zoe secures $770,000 for AI platform supporting neurodivergent kids
Understanding Zoe, an Australian startup helping parents support neurodivergent children, will expand its product and market penetration after securing $770,000 from a leading health-tech investment fund.
Hello Inside Launches in US to Address Women's Metabolic Health Crisis
Hello Inside, a Vienna-based healthtech startup, has officially launched in the US, offering a CGM-enabled app designed for women's health, focusing on hormone balance, menopause, and sustainable weight management. The app utilizes Continuous Glucose Monitoring (CGM) sensors and AI to provide a platform already supporting thousands of women in Europe with metabolic health challenges such as PMS, hormonal balance, and weight management.
Eye-tracking offers measure of change in pre-clinical Alzheimer’s Disease
The study, conducted by the University of Strathclyde and ViewMind, used the ViewMind Atlas™ system, an eye-tracking technology combined with Software as a Medical Device (SaMD). It demonstrated high accuracy in identifying individuals with a genetic predisposition to Alzheimer's Disease before symptoms appear. The technology was 100% accurate for symptomatic individuals and 96% for asymptomatic carriers. This non-invasive method could revolutionize early detection and monitoring of Alzheimer’s, offering a significant advantage over traditional cognitive tests which often fail to detect the disease until symptoms are more pronounced.
President of Estonia visits King's to explore healthcare innovation
On October 14, 2025, His Excellency Alar Karis, President of Estonia, visited King's College London's Guy’s Campus to strengthen Estonia-UK relations and explore healthcare innovation. Accompanied by Estonian Ambassador Sven Sakkov and a delegation of health technology entrepreneurs, President Karis engaged in discussions about research collaboration, particularly in medical solutions to improve healthcare outcomes. The visit included tours of research facilities like the MRC Centre for Developmental Neurobiology and interactions with King’s senior leadership, highlighting the university's commitment to global health challenges and innovation through partnerships with NHS Foundation Trusts and the support for entrepreneurial ventures in health technology.
reach52 Wins Steward Leadership Award for the Fourth Time
reach52, an organization dedicated to improving healthcare access in underserved communities, has won the Steward Leadership Award for the fourth time. This award recognizes their continued efforts in advancing health equity and sustainable impact. With a network of 72,000 rural partner pharmacies and 15,000 community health workers, reach52 has enabled 3.8 million people to access low-cost medicines. The company aims to reach 100 million people by 2030, leveraging technology and community-based care to build more inclusive health systems. This award reaffirms their commitment to driving scalable, sustainable change towards universal health coverage.
reach52's Partnership with Pfizer
Ben Kamarck announced on LinkedIn that reach52 has signed a distribution agreement with Pfizer to provide Sayana Press, a prefilled injectable contraceptive, across Africa for about $1 a month. This initiative, supported by a $600M+ investment from USAID in family planning programs, aims to reduce maternal and child mortality while enabling women and girls to pursue education and livelihoods. The partnership is part of reach52's efforts to create a sustainable commercial model for affordable contraceptives, hoping to encourage investment in health markets that support family planning education.
Facial video photoplethysmography for measuring average and quasi-instantaneous heart rate: a pilot validation study
This study evaluates the accuracy of heart rate (HR) measurements using facial video photoplethysmography (vPPG) technology, Shen.AI Vitals, compared to electrocardiogram (ECG) readings. Conducted on 35 healthy volunteers, the study found that vPPG provided highly accurate HR measurements both for average HR over 60 seconds and for shorter intervals (10 and 4 seconds). The mean absolute errors were minimal, and the correlation with ECG was very strong (r > 0.99). This suggests potential for non-contact HR monitoring in various applications, though further validation in diverse conditions and populations is recommended.
Revolutionizing Medical Diagnostics with PillBot™
Endiatx is transforming the medical diagnostics landscape with its innovative PillBot™, a micro-robot designed to navigate the human body and provide real-time insights. This breakthrough technology aims to replace traditional and often uncomfortable endoscopies, offering a minimally invasive alternative. The development of PillBot™ is supported by the 3DEXPERIENCE Lab, which welcomes the Endiatx team into its acceleration program, highlighting the potential of this technology to redefine medical diagnostics globally.
Qisda Group makes strategic investment in CuboAi, with the original founding team returning to lead the company.
CuboAi has secured a strategic investment from @Qisda Group, which will provide operational support, strengthen financial foundations, and position the company for long-term growth. In addition, the founding team has returned to lead the company forward with a renewed focus on innovation and trust.
Prosoma Secures €500,000 EIT Health Grant
Prosoma has secured a €500,000 grant from EIT Health to expand its digital cancer care services in the DACH region. This funding will support the enhancement of their CE-certified platform, Living Well Plus, which offers psychological and behavioral support to cancer patients through CBT-based modules and access to trained psychologists. The grant will help extend patient support beyond 12 months, expand the sales and partnership team, and foster collaborations with healthcare providers, insurers, and pharma companies, aiming to transform modern healthcare systems with scalable digital solutions.
Breakthrough Study Uses AI to Predict Mental Health Treatment Success
A significant study published in the Journal of Medical Internet Research has introduced a novel approach to mental healthcare by utilizing artificial intelligence to generate objective data on an individual's psychological stress. This data can predict with considerable accuracy who will benefit from specific mental health interventions. This method offers a promising alternative to traditional subjective assessments and could revolutionize precision psychiatry, making it more efficient and accessible.
Verge HealthTech Fund- Creating Healthcare access through Technology
The Verge HealthTech Fund, based in Singapore, focuses on improving healthcare access in low- and middle-income countries by investing in early-stage healthtech startups. Key investments include reach52, a startup that connects rural communities with healthcare services using a tech-enabled platform. Since its inception in 2018, Verge has impacted 22 million lives, with 98% of beneficiaries in LMICs. reach52 has expanded its operations to several countries in Asia and Africa, achieving significant health outcomes like improved vaccination rates and prenatal care attendance. Verge's investment strategy emphasizes sustainable growth, adaptability, and creating pathways for additional capital, ensuring long-term impact and commercial viability.
Forbes Asia 100 To Watch 2025
Health2Sync, a company focused on digital health solutions for chronic disease management, has been named to Forbes Asia’s '100 to Watch 2025' list. This prestigious recognition highlights only three companies from Taiwan, emphasizing Health2Sync's significant impact in the biotechnology and healthcare sectors across the Asia-Pacific region. The company is celebrated for its innovative approach to healthcare, leveraging data and AI to drive personalized health management services. This accolade underscores the potential and influence of digital health innovations in transforming chronic disease care.
From Headsets to Healing: The Rise of Wearable Brain Tech and Its Impact on Mental Illness and Cognitive Health
The article discusses the advancements in noninvasive brain-machine interfaces (BMIs) that are becoming increasingly consumer-friendly. These devices, which do not require surgery or implants, are used to treat mental health issues like depression, anxiety, and PTSD, as well as pain management and insomnia. Companies like Flow Neuroscience and Magnus Medical are at the forefront, developing devices that use electrical and magnetic stimulation to modulate brain activity for therapeutic purposes. The article highlights the potential of these technologies to offer effective, personalized treatments without the side effects associated with traditional drug therapies. It also addresses the challenges such as variability in effectiveness, potential for user error, and insurance coverage issues.
BrainCapture's Product Launch in Indonesia
Paul Loomis shared a post on LinkedIn about the successful product launch of an EEG technology in Indonesia by his company. The event was highlighted by unique LED dancers, emphasizing the cultural integration and local partnership with Wellesta. Indonesia, with its vast market and strong public healthcare, is seen as a strategic location for expanding EEG technology access. The launch aims to double EEG availability in both outpatient and inpatient settings within 1-2 years, leveraging Indonesia's $1.37 trillion economy and large population spread across numerous islands.
German Pharmaceutical Company Backs Two Kenyan Health Startups
Boehringer Ingelheim, a German pharmaceutical company, has expanded its Social Engagement Fund portfolio by investing in two Kenyan health startups, Kasha Global and Reach52. These startups are focused on improving healthcare access in underserved communities. Kasha Global, based in Nairobi, provides a digital and offline health platform that delivers pharmaceuticals and personal care products to low-income areas. Reach52 offers a complementary service by training community health workers, running mobile health campaigns, and facilitating access to affordable medicine in regions with weak healthcare systems. The investments aim to enhance healthcare delivery at the community level and support the startups' expansion across Africa.
Scalable Precision Psychiatry With an Objective Measure of Psychological Stress: Prospective Real-World Study
Mobio Interactive shares significant advancements in precision psychiatry through a recent study published in JMIR. The study involved nearly 3,000 patients using Mobio's mobile health platform, demonstrating that a rule-based algorithm, trained with unbiased, objective data obtained from patients' front-facing cameras, can effectively predict the most beneficial forms of psychotherapy for individual patients. This method, which does not require AI, outperformed patient-selected therapies and represents a major step towards scalable, objective mental health care. The approach eliminates the need for invasive procedures like blood work or brain scans, making it accessible to a wider population regardless of socio-economic status. The study is part of ongoing research to refine and expand the data sources used for these predictions, contributing to the #BrainEconomy movement.
VitruvianMD was one of six innovative South African startups selected to pitch at a private tech mixer
VitruvianMD, a South African startup, was one of six companies selected to pitch at a private tech mixer hosted by RMB - Rand Merchant Bank, in partnership with Launch Africa Ventures, Endeavor, and Saïd Business School, University of Oxford alumni. Co-founder Frando Lin presented their AI-powered fertility technology, which garnered interest from venture capitalists and corporate innovators. The event highlighted VitruvianMD’s commitment to advancing healthcare innovation through AI diagnostics, promising future developments in accessible and effective healthcare solutions.
Lifeyear Secures €2.8M to Accelerate Digital Cardiovascular Care in the UK
Lifeyear, a UK-Estonian healthtech startup, has raised €2.8 million to launch its remote patient management platform aimed at providing digital cardiovascular care. This funding will support the deployment of Lifeyear's platform across various UK healthcare settings like hospitals, GP practices, and virtual wards. The platform is designed to reduce the need for in-person visits, streamline patient monitoring, and ensure compliance with NHS standards. The funding includes contributions from venture capital funds and a significant grant from the Estonian government. Lifeyear's approach combines UK clinical expertise with Estonian tech innovation, aiming to address the increasing burden of cardiovascular diseases in the UK.
Mobio Interactive's Recent Study on Mindfulness-Based Meditation App
Mobio Interactive, a company focused on mental health solutions, recently shared results from a study on their mindfulness-based meditation app, which was conducted in collaboration with CAMH. The study involved several hundred patients on a waitlist for psychiatric services, demonstrating dose-dependent benefits from the app. The app aims to provide immediate mental healthcare and is designed to adapt to various languages and cultural contexts, enhancing accessibility and effectiveness. This approach aligns with Mobio's commitment to scalable and localized mental health solutions.
10 Innovators Making Healthcare More Accessible with AI
The article discusses the achievements of ten innovators who are leveraging AI to make healthcare more accessible. These innovators are recognized as this year's AI & Health Access Pioneer Award winners. They are transforming healthcare access through various means such as AI-powered virtual platforms, hybrid care models, and AI-driven diagnostics. Innovations include mobile clinics, remote monitoring, non-invasive diagnostic tools, and AI-assisted decision support systems, significantly impacting underserved communities and improving healthcare delivery.
Accelerating Impact and Innovation at Macuject
Macuject, a company led by CEO Devinder Chauhan, has recently secured a new non-dilutive government grant from the Industry Growth Program. This funding is a continuation of support that includes two previous federal grants and signifies strong validation of Macuject's innovative approach in the healthcare sector, particularly in managing retinal diseases. The company focuses on developing AI-driven clinical decision support systems to enhance treatment outcomes for macular degeneration, aiming to prevent blindness. This progress opens opportunities for strategic partnerships and investments, positioning Macuject as a leader in data-driven vision health solutions.
Oculomotor behaviors during visual short-term memory binding in healthy aging
This article provides peer-reviewed validation that ViewMind's approach is scientifically grounded. It proves that the oculomotor behaviors ViewMind tracks are not just "noise" from getting older; they are precise indicators of cognitive health. This supports the mission of using digital biomarkers for the early detection of neurodegenerative diseases by focusing on the specific brain functions (binding) that aging shouldn't touch.
Health needs assessment of rural communities in Asia and Sub-Saharan Africa: a cross-sectional study of selected localities
A recent study published by reach52 in the Journal of Global Health Economics and Policy highlights the health needs of rural communities in Asia and Sub-Saharan Africa. The study found that 45% of chronic disease patients seek more than just medical care; they desire connections with others facing similar challenges. Additionally, over 20% of the rural youth surveyed expressed a preference for receiving health information via digital platforms like Facebook and WhatsApp, underlining the potential of digital tools in rural health education. The study also reaffirms the role of Community Health Workers (CHWs) as a scalable and sustainable solution for improving healthcare delivery in these regions. reach52 is committed to enhancing health access for the 52% of the global population currently underserved.
Endiatx has a new CEO leading the PillBot developer
Endiatx, a medical device company based in Hayward, California, announced a leadership change with Arman Nadershahi taking over as CEO from co-founder Torrey Smith. Nadershahi, previously an intellectual property attorney and co-founder of Proa Medical, brings extensive experience in biotechnology law. The company, known for developing the PillBot, a robotic pill for GI diagnostics, has recently received significant investment from SAGES through its SINC venture capital fund, supporting the advancement of this innovative technology. The PillBot is expected to enhance GI screening and diagnostics, making it faster, simpler, and less invasive. Endiatx is preparing for pivotal trials and aims for FDA clearance by 2025.
Kipuwex and Bepsun Achieve Chinese NMPA Approval, Paving the Way for Market Expansion
Kipuwex AB, in collaboration with Bepsun Eurotech Solution Oy, has received approval from the National Medical Products Administration (NMPA) in China for their remote health monitoring technology, Isogang. This approval enables the distribution and use of Kipuwex's technology in China, marking a significant step in the company's global expansion efforts. The technology, which includes features for non-invasive, real-time monitoring of vital signs such as ECG, heart rate, and respiratory rate, aims to enhance patient care in the Chinese healthcare system. The partnership with Bepsun, which has expertise in medical device distribution in China, is pivotal for navigating the regulatory landscape and facilitating the technology's introduction across Chinese hospitals and clinics.
Innovative Health Monitoring by Shen AI
Shen AI, a pioneering tech startup, has developed a technology that captures health insights from facial video analysis. This technology can identify subtle changes in color, micro-movements, and blood flow dynamics to provide a deeper understanding of a person's health. Founders Przemek Jaworski and Remi Koscielny recently showcased this technology in a webinar, highlighting its ability to monitor heartbeats without physical contact, potentially revolutionizing remote healthcare monitoring.
Health2Sync's Collaboration with Abbott and HPB Wins Award
Health2Sync, in collaboration with Abbott and the Health Promotion Board, has won the Emerging Technology – Healthcare category at the Singapore Business Review SBR Technology Excellence Awards 2025. Their joint initiative, DigiCoach, is a 12-week digital coaching program designed to assist individuals with prediabetes or high BMI in preventing or delaying the onset of diabetes. The program integrates Abbott’s FreeStyle Libre CGM technology with real-time feedback from the Health2Sync app, providing personalized health insights. Over 1,700 participants have joined the initiative, demonstrating significant community engagement and support.
Pathway Sets a New Benchmark for Specialty Medical AI with Transparent Just-in-Time Reasoning
Pathway, a leading healthcare AI company, announced a significant milestone with their medical language model achieving a 96% accuracy on the United States Medical Licensing Examination (USMLE) questions. This marks the highest accuracy reported so far, surpassing other leading systems like Med-Gemini and GPT-03. The update highlights improvements in 'Reasoning and Deep modes' that enhance chain-of-thought analysis and retrieval-augmented generation. Pathway's AI is now utilized by clinicians in over 10,000 care centers, aiding in guideline evidence access, dosage confirmations, and clinical questions. The platform's responses are backed by detailed logic trails linking to specific guidelines or medication labels, ensuring transparency and reliability. Independent academic validation studies are underway to further validate these results. For more information, visit the full release linked [here](https://www.businesswire.com/news/home/20250502879071/en/Pathway-Sets-a-New-Benchmark-for-Specialty-Medical-AI-with-Transparent-Just-in-Time-Reasoning).
Personalized Microbiome Modulation to Improve Clinical Outcomes in Pediatric Inflammatory Bowel Disease: A Multi-Omics and Interventional Approach
Nostra:Biome has announced the publication of their second Microbiome Interventional Study, which has shown significant results in the management of Inflammatory Bowel Disease (IBD) in children. This study is notable for its focus on the pediatric population, making it a rare and potentially unique research in this area. The findings support the role of microbiome modulation in inducing remission and providing broader therapeutic impacts for IBD.
RetiSpec's Recognition in Canadian Health Sector
RetiSpec, a company specializing in the early detection of neurodegenerative diseases through retinal imaging, has been featured in the Toronto Star as one of four promising breakthroughs poised to enhance Canada's health sector. This recognition highlights the innovative approaches and significant potential of RetiSpec's technology in healthcare. For more details, read the full article here: <a href="https://shorturl.at/WUMMV">https://shorturl.at/WUMMV</a>
Impact Ventures by J&J Foundation Invests in reach52
Impact Ventures by J&J Foundation has invested in reach52, a social impact business that is transforming healthcare in rural and hard-to-reach areas through a community-driven model. This model leverages technology, local health networks, supply chain, and public health strategies to provide essential health products and services to the 52% of the world's population that remains unreached. The initiative is spearheaded by Edward Booty, CEO and founder of reach52, who emphasizes the critical need for innovative healthcare solutions due to the growing global population and increasing disease burden. By training community members as Health Educators, reach52 enables these communities to strengthen their healthcare systems internally. The company also addresses supply gaps in essential medicines and healthcare products through data-driven distribution systems. Dana Deardorff, Global Director at Impact Ventures, highlighted the investment as a commitment to expanding essential health services using scalable, data-driven solutions.
Impact Ventures by J&J Foundation Invests in Mobio Interactive
Impact Ventures by J&J Foundation has made a significant investment in Mobio Interactive, a company dedicated to revolutionizing mental health care with 'precision psychiatry at scale.' Founded in 2015, Mobio Interactive has developed a technology that uses a phone camera to measure psychological stress through changes in blood vessel colors in the face, a method called remote photoplethysmography (rPPG). This innovative approach allows for the quantification of stress without the need for wearables, making it more accessible to patients worldwide. Mobio Interactive's platform processes a 30-second selfie to provide clinicians with real-time insights into the mental and physical health of their patients. The technology has been supported by a strong body of clinical evidence, with over 20 studies conducted to ensure its efficacy and reliability. The company has amassed a significant dataset with more than 425,000 selfie scans and 3.5 million unique data points, which continues to grow. The investment from Impact Ventures aligns with Mobio's mission to address the paradox in mental health care—those who need it the most often have the least access. The company has already initiated projects in regions like Southwestern India and has partnerships with major healthcare institutions in Singapore and Canada. These collaborations aim to integrate Mobio's technology into local healthcare systems, telehealth networks, and government initiatives globally. Supporting investors include Verge HealthTech, Australian Medical Angels, and Blue Ash Ventures. This backing underscores the potential of Mobio's technology to transform mental health care by making it more objective, accessible, and scalable. The recent funding round will further enable Mobio to expand its research pipeline across various mental health conditions and pursue necessary regulatory approvals.
New Advances in Alzheimer's Detection: Ocular Biomarkers
The Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator has published a pioneering study on ocular biomarkers for early Alzheimer's detection. This study, appearing in Alzheimer’s & Dementia, explores the potential of ocular tests, such as retinal scans, as non-invasive tools alongside blood biomarkers for identifying at-risk individuals. These ocular biomarkers could be integrated into routine eye exams, offering a cost-effective, accessible method for early detection. The paper emphasizes the importance of setting high standards for these tests to ensure reliability and effectiveness in clinical settings.
Sooma Medical Announces Pivotal FDA IDE Clinical Trial for At-Home Brain Stimulation Device for Depression Treatment
Sooma Medical has announced a significant advancement in depression treatment with the FDA IDE approval to begin a pivotal clinical trial for their at-home brain stimulation device, Sooma tDCS. This trial, led by Dr. Christopher Reist, aims to enroll 200 participants across the U.S. in partnership with Lindus Health. The successful trial could lead to a new, non-invasive, and drug-free treatment option for depression in the United States. Links to the full story and subscription for clinical trial updates are available in the comments.
Celebrating HealthTech 250: Advancing Women's Health
Galen Growth's recent LinkedIn post highlights the significant contributions of the HealthTech 250 startups in advancing women's health. These startups are celebrated for their efforts in closing the gender health gap, showcasing a commitment to making women's health a priority rather than an afterthought. The post includes links to various companies like Alife, Aveta.Life, Axena Health, Canopie, and many others, each playing a crucial role in this sector. The initiative not only supports technological advancements but also emphasizes the importance of women's health in the healthcare industry.
Health2Sync Raises US$20M in Series C to Fuel Growth and Taiwan IPO
Health2Sync, a company focused on transforming chronic disease management through digital solutions, has successfully raised $20 million in Series C funding. This significant financial boost aims to accelerate the company's growth, expand into new markets, and prepare for a public listing in Taiwan. The funding round was led by Taiwania Capital and will support new programs for weight management, hypertension, and GLP-1 support, further expansion in Japan, South Korea, and Australia, and the launch of their AI-powered insulin dosage software, Insultrate. Health2Sync's mobile app helps nearly 1.5 million users in multiple countries to manage their chronic conditions like diabetes by tracking blood glucose levels, diet, and medications.
ViewMind Inc.'s Investment Announcement
ViewMind Inc. has received a significant investment of $1.4 million from the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator (DxA). This investment underlines the foundation's dedication to advancing innovative biomarkers and digital health assessments. ViewMind Inc. is recognized for its pioneering brain health assessment technology, ViewMind Atlas™, which utilizes eye movement and pupillometry data. This technology facilitates the early detection of neurological conditions and monitors treatment impacts, offering a non-invasive, scalable, and accurate method for evaluating cognitive brain health. The investment aims to support the development and accessibility of functional brain assessments that are crucial for early diagnosis and treatment monitoring in conditions like Alzheimer's.
Hi Ventures Introduces the First Map of Early-Stage AI Startups in Latin America
Hi Ventures has introduced the first comprehensive map of early-stage AI startups in Latin America. This initiative highlights the growing influence of AI across various sectors including healthcare, finance, logistics, education, and more. The map was compiled using Hi Ventures' proprietary database and Crunchbase, focusing on startups that have raised between $1 million and $10 million. This effort showcases a vibrant AI ecosystem and the innovative solutions emerging from the region, aiming to optimize operations and pioneer new technologies in multiple fields.
Trust Your Gut? Forget Motivation—Discipline Is What You Need
Calin Popescu, a serial entrepreneur and tech inventor, shares his journey of founding NostraBiome, a startup focused on improving gut health through microbiome intelligence. From his early days leaving Romania to work in global tech companies, Popescu delves into the challenges and lessons learned in the startup world. He emphasizes the importance of discipline over motivation and discusses the critical role of resilience in overcoming the hurdles that cause many startups to fail. This story not only highlights the entrepreneurial spirit but also sheds light on the often-overlooked aspects of gut health and the potential of biotechnology in this field. The insights shared in this episode of the Startup Talks Podcast are valuable for anyone interested in the realities of startup success and the innovative approaches to health and biotechnology.
Finding Innovative Ways to Enable Governments to Pay for NCD Treatment
The article discusses the growing burden of non-communicable diseases (NCDs) and the financial challenges governments face in funding their treatment. It highlights various strategies to increase domestic resources for NCDs, such as excise taxes on harmful products, pooled procurement, and incentives for private sector investment. The piece also covers innovative approaches like demand forecasting tools and public-private partnerships to make NCD care more accessible and affordable. Key figures and organizations, such as Reach52 and MedAccess, share insights on overcoming market dynamics and financial risks in the NCD supply chain.
Business school teaching case study: Finding the right prescription
Reach52, a social enterprise founded in 2016 by Edward Booty, aims to improve healthcare access in underserved regions of Asia and Africa. The company uses a network of agents and a sales team to distribute health products to local clinics and pharmacies. It also collaborates with governments and private companies for health campaigns. The case study discusses the challenges Reach52 faces in balancing social impact with commercial sustainability, especially after entering the Indian market by acquiring part of another social business. This expansion has allowed Reach52 to increase its product portfolio and outreach, but also presents strategic dilemmas regarding product selection and sales incentives that align with its dual objectives.
How Reach52 is Bridging the Gap to Ensure Access to Essential Healthcare Services
Reach52, led by CEO Edward Booty, is addressing the critical issue of healthcare access in rural areas where 52% of the population lacks essential services. The company operates in Asia and Africa, using a tech platform to gather health data and provide services like health promotion campaigns and affordable health products in partnership with local entities. The aim is to augment existing services and fill gaps, focusing on rural communities. Edward Booty emphasizes the importance of a multi-partner ecosystem and aims to make a significant impact on healthcare accessibility, measuring success by lives touched and improved.
Improving Lives through Innovation with Steve Atkinson and Helena Binetskaya of ChestPal
Paul-Lukas Hoffschmidt highlighted the significant impact of respiratory diseases in the U.S., with millions suffering chronically. The discussion, featuring Steve Atkinson and Helena Binetskaya on the Alpha Sophia Spotlight podcast, introduced the ChestPal Pro, a smart stethoscope designed to enhance frontline healthcare diagnostics. This innovation aims to improve the accuracy of detecting lung sounds like crackles and wheezes, crucial for diagnosing respiratory conditions. The creators shared insights into the challenges of bringing medical devices to market, including regulatory hurdles and the importance of medical community endorsement.
Robotic Capsule for Endoscopy Launched at AIG Hospitals
AIG Hospitals recently introduced a groundbreaking technology in Hyderabad, the PillBotT, developed by Endiatx. This robotic capsule is designed for endoscopy, equipped with advanced cameras, sensors, and wireless capabilities, allowing it to navigate through the gastrointestinal tract and transmit real-time, high-resolution images to physicians. This innovation aims to enhance diagnostic procedures by being minimally invasive and potentially more cost-effective. The PillBotT is still in clinical trials and has not yet received FDA approval, currently limited to research purposes in India.
Being a Founder Isn't Just Hard—It's Relentless
Remi Koscielny shares insights on the relentless nature of being a founder in a LinkedIn post. He discusses the pressures and challenges of keeping a venture running, drawing from a powerful conversation with his mentor, Farhad Niyoz, as part of the Inner Power Particles podcast. They explore themes such as what drains energy, spotting energy vampires in teams, and recovering from burnout. The discussion also includes insights from Shen.AI CEO on building high-performing teams and designing energy-giving habits. The post includes links to the podcast for further listening.
VitruvianMD's Innovation Award at the Entrepreneurship World Cup
VitruvianMD, co-founded by Ifthakaar Shaik, recently clinched the 'Innovation in Health and Wellness' award at the Entrepreneurship World Cup. The startup was recognized for its pioneering AI technology designed to enhance sperm selection for IVF treatments by predicting DNA fragmentation levels. This accolade was part of a competitive process involving over 16,000 companies from more than 200 countries, culminating in Riyadh, Saudi Arabia. The event not only highlighted global innovations across various sectors but also allowed VitruvianMD to establish significant connections within the Saudi market, which is seen as strategic for their growth.
Endiatx aims to boldly go beyond traditional endoscopy and, eventually, redefine surgical scale
Endiatx, led by CEO Torrey Smith, is pioneering the development of the PillBot, an ingestible, remote-controlled robot designed for endoscopic procedures. This innovative technology aims to replace traditional, more invasive endoscopies with a less intrusive, more efficient solution. The PillBot, which is currently undergoing clinical trials, is equipped with a camera and can be navigated through the stomach to provide real-time images, potentially transforming gastrointestinal diagnostics. Smith, inspired by both personal experiences and science fiction, envisions future advancements where micro-robots could perform complex surgeries internally. Endiatx's bold approach reflects a shift from incremental innovation to groundbreaking changes in medical robotics, pushing the boundaries of what's possible in medical treatment.
ViewMind Joins Bio-Hermes-002 Landmark Study
ViewMind Inc., a leader in eye movement technology, has announced its participation in the Bio-Hermes-002 study, a comprehensive observational platform designed to evaluate the effectiveness of various blood-based and digital biomarkers in detecting and diagnosing Alzheimer’s disease. The study aims to enhance diagnostic precision by analyzing biomarkers across a broad spectrum of racial and ethnic groups, focusing on inclusivity to address a long-standing gap in Alzheimer’s research. ViewMind’s proprietary technology, ViewMind Atlas™, integrates eye-tracking, artificial intelligence, and Software as a Medical Device (SaMD) to provide functional analysis of brain health. This approach allows for the detection of subtle cognitive changes that may reflect disease progression or measure a patient's response to treatment over time. The inclusion of ViewMind Atlas™ in the Bio-Hermes-002 study provides a unique opportunity to further validate non-invasive methods for early Alzheimer’s detection. Data from the study will be securely stored on the Alzheimer’s Disease Data Initiative’s AD Workbench, a cloud-based platform for sharing and analyzing Alzheimer’s research data. Once the study concludes, this data will be accessible to researchers worldwide, supporting a global effort to improve Alzheimer’s diagnostics and treatment strategies.
Digital Health 50: The most promising digital health startups of 2024
RetiSpec, a company specializing in AI-powered retinal imaging technology for early detection of Alzheimer's disease, has been named to the CB Insights Digital Health 50 list for 2024. This inclusion recognizes the company's innovative contributions to healthcare, emphasizing the importance of early detection and diagnostics in transforming the industry. RetiSpec's technology and efforts have placed it among the world's 50 most promising private digital health companies, highlighting its potential to impact global healthcare positively.
HPB working with tech, healthcare partners to get Singaporeans active and healthy
The Health Promotion Board (HPB) of Singapore is collaborating with technology and healthcare companies to launch two pilot programmes aimed at encouraging healthier lifestyles among Singaporeans. The first programme, DigiCoach, involves up to 2,500 participants using continuous glucose monitoring devices to receive real-time feedback on their glucose levels in relation to diet and physical activity. This initiative is in partnership with Abbott, the manufacturer of the monitoring devices, and Health2Sync, a company specializing in healthcare solutions for pre-diabetes and high body mass index individuals. The second programme, HealthTrack SG, targets 3,500 participants managing conditions such as high blood pressure, diabetes, and high cholesterol. It consolidates data from various tracking applications into a single platform accessible to health coaches at Fullerton Health for personalized counselling. This project is a collaboration with Google, Singapore-based health tech company ConnectedLife, and Fullerton Health. These initiatives align with Singapore's Healthier SG strategy, focusing on preventive healthcare and personalized health plans. By integrating wearable technology and real-time data, HPB aims to empower individuals to make informed lifestyle choices, thereby preventing or managing chronic conditions. Through these pilots, HPB seeks to evaluate the effectiveness of such technologies in promoting healthy behaviors and to explore the potential for scaling these solutions to benefit a broader population.
Innovative Glucose Event Hosted by HELLO INSIDE
HELLO INSIDE, led by Mario Aichlseder, organized an innovative event in Berlin at SoHo House, focusing on metabolic health through interactive glucose monitoring. The event, which had only five weeks of preparation, featured 50 selected guests including key opinion leaders and health experts. Guests were provided with Continuous Glucose Monitors (CGM) to engage with the content on a personal level. The event aimed to redefine traditional conference formats by integrating practical health insights with technology, offering a unique experience that combined freshly cooked meals, practical examples, and expert discussions. Keynote speakers included Ida Tin, Nina Ruge, and Dr. Kati Ernst, among others, with support from partner DocMorris.
Vitruvian MD wins the Innovation Track at the Entrepreneurship World Cup
Ifthakaar Shaik of Vitruvian MD for winning the Innovation Track at the Entrepreneurship World Cup with a $50,000 prize!
AI in Mental Health: A Talk by Bechara Saab
Bechara Saab, CEO and Chief Scientist at Mobio Interactive, recently delivered a 45-minute talk on the use of AI in measuring mental health without bias. The talk, hosted by the Colombian Ministry of Technology, covered various AI technologies including applications in fMRI and verbal analysis. Saab highlighted the deep tech developments and commercial applications by Mobio Interactive. The event also featured an engaging Q&A session. Partners from LATAM Corporate Development, Diana Gaviria and Verónica Dávila, were also present, appreciating the initiative towards unbiased mental health solutions.
Malaria workshop equips laboratory technicians
Carnegie Mellon University Africa's AI Healthcare Research Laboratory, in collaboration with the University of Rwanda, Rwanda Biomedical Centre, and several district laboratories from Rwanda, hosted a three-day workshop aimed at revolutionizing malaria microscopy through advanced digital data collection techniques. Held from October 8-10, the workshop trained laboratory technicians on using high-resolution microscopes, digital cameras, and specialized laptops to digitize malaria diagnosis processes. The training covered technical aspects of the VMD system, biological identification of malaria parasites, and practical skills in microscope operation and digital image capturing. The initiative is part of ongoing efforts to enhance malaria diagnostics in Rwanda using robust digital methodologies.
CuboAi completed Series B fundraising of 110 million and will launch a new AI product "Baby Growth Diary" by the end of the year
Taiwanese mother-and-baby tech startup CuboAi (Yunyun Technology) announced the successful completion of a Series B funding round, raising NT$110 million. Founded in 2017, CuboAi combines AI with smart parenting devices to address traditional childcare challenges. Its flagship smart baby camera and related products have sold over 250,000 units, with 80% of revenue from overseas markets. The funds will support new AI product development, including the "Baby Growth Diary," which tracks various health metrics, and the "Growth Tracking" feature for automated height measurement. CuboAi continues expanding globally, establishing strong retail partnerships, especially in Japan, where it leads in Amazon sales.
Health2Sync Offers Diabetes Management Solutions to Users Worldwide
Health2Sync, founded in 2013 by Ed Deng, Ken Lai, and Erin Chung, is a digital platform designed to assist individuals with diabetes manage their condition more effectively. The platform leverages technology to connect patients with healthcare providers through its app and cloud-based system, facilitating better diabetes management. Health2Sync has conducted significant research, published on PubMed, showing the effectiveness of their app in improving glycemic control among users. The app includes features such as blood glucose tracking, medication reminders, and the ability to connect with healthcare professionals and family for support. Health2Sync has expanded globally, serving users in multiple countries and languages, integrating with other health apps and devices to provide comprehensive health data.
Understanding the limitations of previous microbiome studies and Nostra:Biome’s holistic approach to effective personalized microbiome modulation
This article explores the shortcomings of past microbiome studies and introduces NostraBiome's innovative approach to personalized microbiome therapies. Traditional studies often faced issues like small sample sizes and low-resolution analytical methods, which limited their effectiveness. NostraBiome emphasizes the uniqueness of each individual's microbiome and its interactions with the immune system, focusing on personalized inflammatory signatures and integrating advanced technologies to overcome these limitations and advance microbiome-based therapies.
CHISEL Healthcare InnoMatch 2024
The Centre for Healthcare Innovation (CHI) successfully concluded the CHISEL Healthcare InnoMatch 2024, an initiative designed to foster innovation in healthcare. This event saw participation from 330 startups and SMEs across 50 countries. In a competitive finale attended by over 200 industry stakeholders, three winners were selected, sharing S$1.5 million in test-bedding funds. The winners, CAPTUREPROOF, SG Diagnostics, and ViewMind Inc., showcased solutions in digital health, chronic disease management, and cognitive health assessment, respectively. These innovations aim to enhance patient care and improve health outcomes. The event is part of CHI’s broader mission to support healthcare innovation and leadership through various programs and partnerships.
This is how depression can be treated at home: the patient gives themselves electricity several times a week
In Finland, a new method called transcranial direct current stimulation (tDCS) is being used to treat depression in the workplace. This method involves wearing a cap embedded with electrodes that deliver a low-level electrical current to stimulate the brain. The treatment, which is not covered by national health insurance, involves sessions of 30 minutes per day, five days a week for six weeks. It is particularly effective in the early stages of mild to moderate depression and can enhance the patient's sense of agency, making them feel they can actively contribute to their own recovery. The device used for this treatment has been developed by the Finnish company Sooma, and it requires a mobile app to operate. This innovation is part of a broader trend towards digital self-care devices in occupational health services, which are rapidly becoming more common as they offer a cost-effective solution for managing health issues in the workplace.
Funding boost helps BrainCapture bring EEG technology to underprivileged regions
Danish healthtech startup BrainCapture has received a significant investment from Verge HealthTech Fund to expand its innovative EEG technology to underserved regions. BrainCapture's portable BC-1 EEG system, which combines AI, smartphone technology, and automation, aims to make neurological diagnostics accessible in areas with limited healthcare infrastructure. The system has been trialed successfully in Africa and Asia, demonstrating its potential to provide high-quality diagnostics without the need for expensive equipment or specialist knowledge. This funding will help scale production and expand services, addressing the global health challenge of providing reliable neurological diagnostics to over four billion people lacking access.
AI Company puts Romania on world map of medical breakthroughs
The article discusses the achievements of NostraBiome, a Romanian startup founded by Călin Popescu. This company, using Artificial Intelligence, has developed innovative medical solutions that significantly improve the treatment of various diseases by analyzing and modifying the microbiome. Popescu, initially motivated by his own health struggles, has led the company to create a system that offers personalized medical recommendations based on detailed microbiome analysis. The company has seen a 100% positive response rate in its initial trials and is now aiming to expand its research and applications, particularly in oncology. Nostra Biome represents a significant advancement in health technology, emphasizing a personalized approach to medicine, and is poised for international expansion.
Building the First Biotech Unicorn in Eastern Europe — NostraBiome path
Calin Popescu shares his journey of creating NostraBiome, a biotech startup aiming to become the first unicorn in Eastern Europe. Popescu, a serial entrepreneur and innovator, has a history of suffering from Inflammatory Bowel Disease (IBD) for 12 years with no effective treatment. This personal struggle led him to explore the microbiome's role in health, eventually founding NostraBiome. The company has developed a breakthrough that enhances existing therapies by focusing on the microbiome, showing promising results in improving treatment responses significantly. NostraBiome not only aims to revolutionize biotech but also to improve millions of lives by addressing overlooked aspects of health through a deep understanding of microbiome interactions.
Building Romania’s next tech ecosystem: A framework for growth and innovation
Romania is poised to become a significant player in the global tech ecosystem, with a growing number of skilled workers and evolving infrastructure. The article outlines a framework for fostering this growth, emphasizing the need for capital attraction, nurturing talent, leveraging remote work trends, and fostering innovation through public-private collaboration. Key strategies include tax incentives for returning diaspora and entrepreneurs, zero-tax schemes for innovative companies, and creating a talent-friendly infrastructure. Additionally, the establishment of a 'Ministry of the Future' is proposed to ensure long-term continuity and predictability in policies, aiming to position Romania as Europe's premier innovation hub.
C100 Announces 2024 Growth and Fellows Program Cohorts
C100, a prominent network supporting Canadian tech entrepreneurship, has launched its 2024 cohorts for the Growth and Fellows Programs. The Growth Program supports scaling companies with over $10M in revenue, including diverse industries like B2B SaaS, fintech, and AI. The Fellows Program, now in its 15th year, supports early-stage companies with a focus on technological and social impact. Both programs aim to connect Canadian tech leaders with resources, mentorship, and networks to foster significant growth and global impact.
Why running a startup is like playing 3-D chess, says Reach52’s Edward Booty
Edward Booty, founder of the Singapore-based startup Reach52, likens running a company to playing 3-D chess, emphasizing the constant need for strategic thinking and adaptability. Reach52 aims to improve healthcare and health literacy in rural communities globally, particularly in regions where access to basic healthcare is limited. Booty's journey began with a transformative trip to India, where he was confronted with severe healthcare deficiencies. This experience led him to bootstrap Reach52 in 2017, focusing on affordable medicine, health screenings, and educational outreach. Despite the challenges of low profit margins and high operational costs, Reach52 has made significant impacts, partnering with major pharmaceuticals and expanding its reach to over 2,500 communities across six countries. Booty's approach to funding was to initially use his savings, avoiding early venture capital to maintain a lean operation focused on sustainability and effective business modeling. His personal philosophy centers on solving meaningful problems and maintaining integrity in business decisions, aiming to leave a positive mark through his work.
🎦 Călin Popescu, Nostra Biome: 10 years of suffering that led to the startup that studies the microbiome
Călin Popescu, a Romanian entrepreneur splitting his time between Berlin and Romania, founded Nostra Biome after personally suffering from an inflammatory bowel disease for ten years without effective treatments. Nostra Biome, a med-tech and biotech company, focuses on studying the human microbiome—bacteria, viruses, and other microbes living in the body—and its relationship to overall health. The company develops personalized treatment plans based on microbiome analysis. They have developed a testing kit that sequences microbiome DNA from fecal samples, providing detailed reports and lifestyle and medical recommendations. Supported by a Singapore-based medical investment fund, Nostra Biome aims to extend its research and solutions, potentially exploring areas like oncology and advanced probiotics.
RetiSpec secures $13.8 million Series A to detect Alzheimer’s early through retinal imaging
Toronto-based startup RetiSpec has successfully raised $13.8 million CAD in a Series A funding round to further develop and commercialize its AI-driven eye test for early detection of Alzheimer's disease. The funding round was led by iGan Partners and included significant contributions from strategic investors like Eli Lilly and Topcon Healthcare. RetiSpec's technology aims to detect amyloid burden, a core biomarker of Alzheimer's, through a non-invasive eye test. The startup also plans to participate in a large-scale study with the Global Alzheimer’s Platform Foundation to validate its technology, which could revolutionize early diagnosis and treatment approaches for neurodegenerative diseases.
No stories match your search.